Abstract
Chimeric antigen receptor T cell (CAR-T) therapies are now standard-of-care for several B-cell malignancies, and additional indications are being evaluated. In this review, we survey data on how outcomes after...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have